艾芦库单抗

艾芦库单抗
单克隆抗体
种类完整抗体
目標VEGFR（英语：VEGF receptor）-1
臨床資料
其他名稱IMC-18F1
ATC碼
  • 未分配
识别信息
CAS号1024603-92-6  ☒N
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6514H10024N1756O2032S42
摩尔质量146,796.63 g·mol−1

艾芦库单抗（INN：Icrucumab；开发代号：IMC-18F1）是一种人单克隆抗体，设计用于治疗实体瘤。[1][2]艾芦库单抗由ImClone Systems（英语：ImClone Systems）公司开发，正在进行I期试验。[3]

参考资料

[编辑]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. （原始内容存档 (PDF)于2012-09-28）. 
  2. ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8. 
  3. ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov